SFO
SRPT icon

Standard Family Office’s Sarepta Therapeutics SRPT Stock Holding History

Standard Family Office’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,859
Closed -$378K – 460
2021
Q2 		$378K Buy
4,859
+2,314
+91% +$175K 0.08% 103
2021
Q1 		$190K Buy
2,545
+1,767
+227% +$163K 0.04% 131
2020
Q4 		$133K Buy
+778
New +$115K 0.03% 163

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Standard Family Office's SRPT Position: Q3 2021 in Review

Standard Family Office sold out of Sarepta Therapeutics (SRPT) in Q3 2021, closing a stake of 4,859 shares — an estimated $378K sold.

Standard Family Office first reported a position in SRPT in Q4 2020 and held it in 3 quarters. The position peaked at $378K in Q2 2021. 306 funds tracked by Wall St. Rank hold SRPT as of Q3 2021.

  • Standard Family Office reported no remaining Sarepta Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Standard Family Office sold 4,859 Sarepta Therapeutics shares in Q3 2021, an estimated $378K.
  • Standard Family Office first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 3 quarters.
  • Standard Family Office's Sarepta Therapeutics position peaked at $378K in Q2 2021.
  • 306 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2021.

Based on Standard Family Office's 13F filing for Q3 2021, filed 15 Nov 2021.